Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

Published Date: 01 Mar 2023

United Kingdom: AstraZeneca has announced that it has received European Union (EU) approval for the immuno-oncology drug combination Imfinzi (active ingredient durvalumab) and Imjudo (tremelimumab).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease

2.

Research uncovers hidden Australian skin cancer epidemic

3.

Immunotherapy and targeted radiation shrink liver tumors, enabling surgery

4.

In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.

5.

The American College of Physicians updated its recommendations for colorectal cancer screening.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot